Story
Asia and Europe Tipped for Equity Market Leadership Over Next 12 Months

Summary
Market analysis suggests Asia ex-Japan offers the highest growth potential, albeit with significant risk, while European equities present a compelling value opportunity as investors look beyond U.S. mega-caps.
Equities in Asia ex-Japan and Europe are positioned for the strongest relative outperformance over the next 12 months, according to recent market analysis, as investors seek opportunities beyond U.S. mega-cap technology stocks. In an environment of rising yields, which tends to increase the appeal of current earnings and cash flow, several global markets are presenting distinct risk-reward profiles.
Asia Leads on Growth Potential
Asia ex-Japan is identified as the region with the highest upside potential, driven by strong investment in artificial intelligence, improving earnings expectations, and more attractive valuations compared to U.S. technology counterparts. Citing this outlook, Standard Chartered recently upgraded the region to Overweight, with a preference for Taiwan and China. The bank projects that Asia ex-Japan will deliver the strongest earnings growth among major markets in 2026 and 2027.
However, this potential is paired with the highest geopolitical risk. Investors must consider potential trade restrictions, volatility in the semiconductor cycle, and the possibility of regional political shocks. The region is therefore framed as a high-upside opportunity rather than a safe haven.
Europe Offers Value and Cyclical Exposure
For investors focused on value and cyclical rotation, Europe emerges as a key opportunity. European equities generally trade at lower valuations than U.S. mega-caps and provide exposure to sectors poised to benefit from current macroeconomic trends.
Key sectors in Europe include:
Ad- Banks and energy, which are favored in a higher-yield environment.
- Defense and industrials, which are supported by increased fiscal spending.
While the fundamental case is strong, analysts caution that daily and weekly technical signals for European indices remain bearish, suggesting that entry timing is a critical consideration for investors.
Japan and Emerging Markets Present Targeted Opportunities
Japan's equity market is supported by a strong structural reform narrative, including corporate governance improvements and a greater focus on shareholder returns. However, the primary risk is the potential for faster-than-expected monetary tightening by the Bank of Japan, which could strengthen the yen and hurt the nation's exporters. Historical analysis from Citi has shown that both Japan and Europe tend to perform well during rate-hiking cycles.
Within emerging markets, Brazil and India offer distinct plays. Brazil is noted for its value and commodity exposure, while India provides a strong domestic growth story, though at a higher valuation. A UBS report highlighted a preference for India, Brazil, Indonesia, and China, but other research has warned that India's earnings expectations may already be priced in.
Read next
More on Stocks
Blue Owl Capital Stock Slides on Oracle Notice for AI Data Center Project
Shares of alternative asset manager Blue Owl Capital fell after Oracle issued a force majeure notice related to a major AI data center campus, raising investor concerns about a key growth project.

Greenland Mines President Sees 'New Opportunities' in US-Denmark-Greenland Pact
The president of Greenland Mines (NASDAQ:GRML) stated that a new strategic agreement between the U.S., Denmark, and Greenland could improve the investment climate for the region's mining sector. The news prompted a sharp rally in the company's shares.

Grail Stock Pauses After Rally on Mixed FDA Panel Vote for Cancer Test
Shares of Grail Inc. are facing pressure after a significant run-up, as investors digest a supportive but not unanimous FDA panel recommendation for its Galleri cancer test and question the stock's current valuation.

Kyverna Shares Surge on Positive One-Year Data for Autoimmune Therapy
Kyverna Therapeutics (NASDAQ:KYTX) stock jumped nearly 10% after the company released positive one-year follow-up data for its CAR T-cell therapy, miv-cel, in patients with two rare autoimmune diseases.